- Email: [email protected]
4923819 Time-resolved fluorescence immunoassay
viii
New Patents
4923813 MONOCLONAL ANTIBODYBASED IMMUNOASSAY FOR CYCLIC DNA ADDUCTS RESULTING FROM EXPOSURE TO CROTONALDEHYDE OR ACROLEIN Stephen S Hecht, Peter G Foiles, Fung-Lung Chung assigned to American Health Foundation Monoclonal antibodies specific for the 8R,6Rand 8S,6S-stereoisomers of 3-(2-deoxy- beta D erythropentofuransyl)-5,6,7, 8-tetrahydro 8 hydroxy-6-methylpyrimido 1,2-a purine10(3H)one were produced. These cyclic I,N2propanodeoxyguanosines are formed in D N A exposed to crotonaldehyde in vitro. Three of the four antibodies were most specific for one stereoisomer while the fourth was most specific for the other stereoisomer. Fifty % inhibition of binding in an enzyme-linked immunoabsorbent assay could be achieved with 0.2 picomol of either stereoisomer. A high-pressure liquid chromatography-enzyme-linked immunoabsorbent assay using two of these antibodies and capable of detecting 0.5 mumol of 1,N2propanodeoxyguanosine per mol of deoxyguanosine was developed. The method was validated by comparison to results obtained with fluorescence assay.
Disclosed are specific aminoalkyl naphthalenediol derivatives that enhance natural human host resistance to viral infectious organisms and particularly AIDS-related viruses. Such agents are also administered prophylactically to individuals whose resistance to infection has been specifically immunocompromised by an AIDS-related (HIV) virus.
4923895 METHOD OF TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS Mont Ho, Phalguni Gupta assigned to University of Pittsburgh of the Commonwealth System of Higher Education A method of treating a patient for human immunodeficiency virus (HIV) includes administering to the individual patient intravenously a therapeutically effective dosage of oxyphenarshine (3 amino-4 hydroxyphenylarsineoxide hydrochloride). The dose emplyed may be up to about 1 milligram per kilogram of body weight administered 1 to 2 times weekly. The oxyphenarsine is preferably administered in such an amount as to achieve in said patient a blood serum concentration of about 0.12 to 6.0 micrograms per milliliter.
4925648 4923819 TIME-RESOLVED FLUORESCENCE IMMUNOASSAY Salvador M Fernandez, Hann-Ping Wang, Yong-Sheng Chao, Ernest Guignon assigned to Chimerix Corporation Fluorescence immunoassay for determining single or multiple analytes based upon a single measurement of fluorescence are described.
4923852 AMINOALKYL NAPHTHALENEDIOLS AS HOST RESISTANCE ENHANCERS AGAINST VIRAL INFECTIONS Philippe L Durette assigned to Merck & Co lnc
DETECTION AND TREATMENT OF INFECTIOUS AND INFLAMMATORY LESIONS Hans J Hansen, Milton D Goldenberg assigned to Immunomedics Inc A polyspecific anti-leukocyte antibody conjugate for targeting foci of leukocyte accretion comprises an immunoreactive polyspecific composite of at least two different substantially monospecific antibodies or antibody fragments, conjugated to at least one imaging agent, wherein at least two of said antibodies or antibody fragments specifically bind to different leukocyte cell types. A method for targeting an imaging agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above anti-leukocyte imaging conjugate. A therapeutic anti-leukocyte antibody-agent conjugate for targeting foci of leukocyte accretion comprises at least one immunoreactive substan-
New Patents
4923813 MONOCLONAL ANTIBODYBASED IMMUNOASSAY FOR CYCLIC DNA ADDUCTS RESULTING FROM EXPOSURE TO CROTONALDEHYDE OR ACROLEIN Stephen S Hecht, Peter G Foiles, Fung-Lung Chung assigned to American Health Foundation Monoclonal antibodies specific for the 8R,6Rand 8S,6S-stereoisomers of 3-(2-deoxy- beta D erythropentofuransyl)-5,6,7, 8-tetrahydro 8 hydroxy-6-methylpyrimido 1,2-a purine10(3H)one were produced. These cyclic I,N2propanodeoxyguanosines are formed in D N A exposed to crotonaldehyde in vitro. Three of the four antibodies were most specific for one stereoisomer while the fourth was most specific for the other stereoisomer. Fifty % inhibition of binding in an enzyme-linked immunoabsorbent assay could be achieved with 0.2 picomol of either stereoisomer. A high-pressure liquid chromatography-enzyme-linked immunoabsorbent assay using two of these antibodies and capable of detecting 0.5 mumol of 1,N2propanodeoxyguanosine per mol of deoxyguanosine was developed. The method was validated by comparison to results obtained with fluorescence assay.
Disclosed are specific aminoalkyl naphthalenediol derivatives that enhance natural human host resistance to viral infectious organisms and particularly AIDS-related viruses. Such agents are also administered prophylactically to individuals whose resistance to infection has been specifically immunocompromised by an AIDS-related (HIV) virus.
4923895 METHOD OF TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS Mont Ho, Phalguni Gupta assigned to University of Pittsburgh of the Commonwealth System of Higher Education A method of treating a patient for human immunodeficiency virus (HIV) includes administering to the individual patient intravenously a therapeutically effective dosage of oxyphenarshine (3 amino-4 hydroxyphenylarsineoxide hydrochloride). The dose emplyed may be up to about 1 milligram per kilogram of body weight administered 1 to 2 times weekly. The oxyphenarsine is preferably administered in such an amount as to achieve in said patient a blood serum concentration of about 0.12 to 6.0 micrograms per milliliter.
4925648 4923819 TIME-RESOLVED FLUORESCENCE IMMUNOASSAY Salvador M Fernandez, Hann-Ping Wang, Yong-Sheng Chao, Ernest Guignon assigned to Chimerix Corporation Fluorescence immunoassay for determining single or multiple analytes based upon a single measurement of fluorescence are described.
4923852 AMINOALKYL NAPHTHALENEDIOLS AS HOST RESISTANCE ENHANCERS AGAINST VIRAL INFECTIONS Philippe L Durette assigned to Merck & Co lnc
DETECTION AND TREATMENT OF INFECTIOUS AND INFLAMMATORY LESIONS Hans J Hansen, Milton D Goldenberg assigned to Immunomedics Inc A polyspecific anti-leukocyte antibody conjugate for targeting foci of leukocyte accretion comprises an immunoreactive polyspecific composite of at least two different substantially monospecific antibodies or antibody fragments, conjugated to at least one imaging agent, wherein at least two of said antibodies or antibody fragments specifically bind to different leukocyte cell types. A method for targeting an imaging agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above anti-leukocyte imaging conjugate. A therapeutic anti-leukocyte antibody-agent conjugate for targeting foci of leukocyte accretion comprises at least one immunoreactive substan-